243 related articles for article (PubMed ID: 32656818)
21. Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Sang A; Zhuo S; Bochanis A; Manautou JE; Bahal R; Zhong XB; Rasmussen TP
BioDrugs; 2024 Jun; ():. PubMed ID: 38914784
[TBL] [Abstract][Full Text] [Related]
22. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks.
Nakamura A; Ali SA; Kapoor M
Bone; 2020 Sep; 138():115461. PubMed ID: 32485363
[TBL] [Abstract][Full Text] [Related]
23. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design of antisense oligonucleotides that inhibit SARS-CoV-2 replication.
Li Y; Garcia G; Arumugaswami V; Guo F
bioRxiv; 2021 Aug; ():. PubMed ID: 34462746
[TBL] [Abstract][Full Text] [Related]
25. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
26. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
[TBL] [Abstract][Full Text] [Related]
27. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
[TBL] [Abstract][Full Text] [Related]
28. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
29. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
Bizot F; Vulin A; Goyenvalle A
Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
[TBL] [Abstract][Full Text] [Related]
30. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
[TBL] [Abstract][Full Text] [Related]
31. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
Delihas N
Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
[TBL] [Abstract][Full Text] [Related]
32. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
34. Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights.
Ersöz E; Demir-Dora D
Drug Dev Res; 2024 Jun; 85(4):e22187. PubMed ID: 38764172
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Hammond SM; Abendroth F; Gait MJ; Wood MJA
Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
[TBL] [Abstract][Full Text] [Related]
36. Advances in therapeutic bacterial antisense biotechnology.
Hegarty JP; Stewart DB
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
[TBL] [Abstract][Full Text] [Related]
37. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
38. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.
Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F
Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases.
Verma A
Ann Indian Acad Neurol; 2018; 21(1):3-8. PubMed ID: 29720791
[TBL] [Abstract][Full Text] [Related]
40. Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop.
Stephenson D; Belfiore-Oshan R; Karten Y; Keavney J; Kwok DK; Martinez T; Montminy J; Müller MLTM; Romero K; Sivakumaran S
Neurotherapeutics; 2023 Oct; 20(6):1682-1691. PubMed ID: 37823970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
